Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of submicronic liposomes.
Abstract
Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of submicronic oligolamellar liposomes, the wall of which consists of lipids and optionally a substance A and the core of which consists of water or an aqueous solution, and optionally containing a substance B, characterised in that: (1) a liquid phase is prepared, consisting essentially of a solution of the lipids and optionally of the substance A in a solvent or in a solvent mixture, and which can contain the substance B in solution, (2) a second liquid phase is prepared, consisting essentially of water or an aqueous solution of the substance B, (3) the first phase is added with moderate agitation to the second phase so as to obtain a colloidal suspension of liposomes and (4) if so desired, all or part of the solvent or solvent mixture and water is removed so as to obtain a colloidal suspension having the desired liposome concentrations. Applications: medicinal products, cosmetic products.
Term
Term ended
Projected expiry passed 28 June 2009, 17.2 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
10 claims: 1 independent, 9 dependent
- c-fr-00011. Process for the preparation of dispersible colloidal systems of amphiphilic lipids, in the form of oligolamellar liposomes submicron whose wall is constituted by the said lipids and optionally a substance A and the nucleus of which is constituted by water or a aqueous solution, optionally containing a substance B, characterized in that:(1) preparing a liquid phase consisting essentially of a solution of said lipids and optionally by substance A in a solvent or in a mixture of solvents, and which may contain substance B in solution,(2) preparing a second liquid phase consisting essentially of water or an aqueous solution of substance B,(3) is added, with moderate stirring, the first phase to the second phase, so as to obtain almost instantaneously a colloidal suspension of liposomes,(4) if desired, are removed all or part of the solvent or mixture of solvents and water, so as to obtain a colloidal suspension of desired liposome concentration.
40 paragraphs, as filed
The present invention relates to a process for the preparation of dispersible colloidal systems of amphiphilic lipids, in the form of submicron oligolamellar liposomes.
There are numerous documents describing the preparation and use of liposomes, particularly as carriers of biologically active substances such as drugs, proteins, enzymes, diagnostic agents or cosmetics. Thus, water-soluble substances can be encapsulated in the aqueous spaces of the liposome, or lipophilic materials may be incorporated in the lipid wall.
Systems a process for preparing oligolamellar vesicle has already been described by Bangham et al. (J. Mol. Biol.<u>13</u>, 238-252; 1965). According to this method, the lipids and lipophilic substances are dissolved in an organic solvent and treated with an aqueous phase with vigorous stirring. However, this process, like most known methods derived therefrom, does not allow to directly obtain liposomes of submicron particle size, which would allow a much greater stability of the particles and their dispersions.
The invention provides a simple and widely applicable, liposome preparation of submicroscopic size.
The invention therefore relates to a method of preparation of dispersible colloidal systems of amphiphilic lipids, in the form of oligolamellar liposomes submicron whose wall is constituted by the said lipids and optionally a substance A and the nucleus of which is constituted by, the water or an aqueous solution and containing rently Even a substance B, characterized in that:<ul><li>(1) a liquid phase is prepared constituted essentially by a solution of amphiphilic lipids and optionally of substance A in a solvent or in a mixture of solvents, and which may contain substance B in solution,</li><li>(2) preparing a second liquid phase consisting essentially of water or an aqueous solution of substance B,</li><li>(3) is added, with moderate stirring, the first phase to the second phase, so as to obtain almost instantaneously a colloidal suspension of liposomes,</li><li>(4) if desired, are removed all or part of the solvent or mixture of solvents and water, so as to obtain a colloidal suspension of desired liposome concentration.</li></ul>
The substance A, lipophilic, is intended to modify the physical characteristics (electrical load, stiffness) or chemical from the wall. It may be cholesterol, stearylamine, phosphatidic acid, alpha-tocopherol, a nonionic surfactant, etc ...
Substance B is a biologically active substance, in particular a medicinal active principle or a medicinal precursor, a biological reagent or a cosmetic product, the substance B is introduced in step (1) if it is lipophilic and in step (2) if it is hydrophilic.
The amphiphilic lipids can be glycolipids, phospho-aminolipids, and in particular phospholipids, such as lecithins (egg, soybean, etc ...).
The solvent is preferably an alcohol miscible with water in all proportions, in particular ethanol.
The lipid concentration in the solvent may be from 0.1 to 10% by weight, preferably 1 to 5% by weight.
It is advantageous that the volume of solvent used for step (1) is between 5 and 100%, for example about 50%, the volume of water of step (2), in order to obtain small liposomes (in particular from 100 to 300 nm).
The expression "moderate stirring" agitation such as magnetic stirring, 10 to 500 rpm, for example about 100 rpm.
Thus, the invention provides drugs, including injectable form, and cosmetics that are very stable.
The following examples illustrate the invention.
example 1
Preparation of liposomes.
organic phase 1
soy lecithin (Epikuron 170) 2.0 g 50.0 g absolute ethanol
aqueous phase 2
Water 100.0 g
Phase 1 is added with magnetic stirring to Phase 2. The medium immediately becomes opalescent by formation of liposomes. The average size of the liposomes, measured immediately after preparation, in a laser beam diffractometer (Nanosizer<sup>R</sup> of Coultronics), is 180 nm with an average dispersion index of 0.5.
The alcohol was removed under reduced pressure, and the liposome suspension was filtered through a sintered glass (9-15 nm pore).
The size of the liposomes, measured again in the filtrate remains unchanged.
The review by transmission microscopy shows oligolamellar liposomes of uniform size.
example 2
Preparation of liposomes containing cholesterol (Variant of Example 1).
The procedure is as in Example 1, but adding 0.30 g of cholesterol in the alcoholic phase. The liposomes obtained have the same characteristics as in Example 1.
example 3
: Variant of Example 1.
The procedure is as in Example 1, but replacing soybean lecithin of egg lecithin. The obtained liposomes have the same characteristics as in Example 1.
example 4
: Variant of Example 2.
The procedure is as in Example 2, but replacing soybean lecithin of egg lecithin. The obtained liposomes have the same characteristics as in Example 1.
example 5
Preparation of liposomes containing a hydrophilic active principle.
The procedure is as in Example 2 but adding 0.20 g of ampicillin (sodium salt) in the aqueous phase.
The incorporation rate of ampicillin in the liposomes, measured after separation of the liposomes from the aqueous phase by chromatography on Sephadex gel is 10%.
example 6
Preparation of liposomes containing a lipophilic active principle.
The procedure is as in Example 1, but adding 66.7 mg of muramyl tripeptide-cholesterol in the organic phase. The incorporation rate of the active ingredient is 100%.
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| WO9936104A3 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| AU2006200015B2 | Cited by | Australia | Search report |
| US10220104B2 | Cited by | United States of America | Applicant |
| US10583207B2 | Cited by | United States of America | Applicant |
| EP1419789A3 | Cited by | European Patent Office (EPO) | Search report |
| IT201900004877A1 | Cited by | Italy | Applicant |
| WO9116039A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| WO9206666A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| AU651969B2 | Cited by | Australia | Search report |
| US9789210B1 | Cited by | United States of America | Applicant |
| US11266750B2 | Cited by | United States of America | Applicant |
| US11266749B2 | Cited by | United States of America | Applicant |
| FR2668063A1 | Cited by | France | Search report |
| WO9504523A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| WO9116039A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| US9913919B2 | Cited by | United States of America | Applicant |
| US11344636B2 | Cited by | United States of America | Applicant |
| AU2006200015B8 | Cited by | Australia | Search report |
| EP1419789A2 | Cited by | European Patent Office (EPO) | Search report |
| EP0461333A1 | Cited by | European Patent Office (EPO) | Search report |
| US11395856B2 | Cited by | United States of America | Applicant |
| US10583208B2 | Cited by | United States of America | Applicant |
| US10588988B2 | Cited by | United States of America | Applicant |
| US10022460B2 | Cited by | United States of America | Applicant |
| DE4013580A1 | Cited by | Germany | Search report |
| WO9936104A2 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| EP0130577A2 | Cites | European Patent Office (EPO) | Search report |
| EP0190050B1 | Cites | European Patent Office (EPO) | Search report |
| GB2002319A | Cites | United Kingdom | Search report |
31 members in 10 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 8808874 | France | A | |
| 8808874 | France | – | |
| 8808874 | – | – | – |
| FR19880008874 | – | – | – |
Members31
| Document | Office | Kind | |
|---|---|---|---|
| FR2608942A1 | France | A1 | |
| EP0274961A1 | European Patent Office (EPO) | A1 | |
| JPS63232840A | Japan | A | |
| EP0349429A2This record | European Patent Office (EPO) | A2 | |
| FR2634375A1 | France | A1 | |
| KR900000074A | Republic of Korea | A | |
| JPH02149336A | Japan | A | |
| EP0349429A3 | European Patent Office (EPO) | A3 | |
| FR2608942B1 | France | B1 | |
| FR2634375B3 | France | B3 | |
| US5049322A | United States of America | A | |
| CA1293170C | Canada | C | |
| EP0274961B1 | European Patent Office (EPO) | B1 | |
| AT74025T | Austria | T | |
| DE3777793D1 | Germany | D1 | |
| ES2031529T3 | Spain | T3 | |
| US5174930A | United States of America | A | |
| EP0349429B1 | European Patent Office (EPO) | B1 | |
| AT85888T | Austria | T | |
| GR3004198T3 | Greece | T3 | |
| DE68904999D1 | Germany | D1 | |
| GR3007265T3 | Greece | T3 | |
| DE68904999T2 | Germany | T2 | |
| ES2054053T3 | Spain | T3 | |
| JPH0693998B2 | Japan | B2 | |
| JPH0824840B2 | Japan | B2 | |
| KR960014869B1 | Republic of Korea | B1 | |
| EP0349429B2 | European Patent Office (EPO) | B2 | |
| ES2054053T5 | Spain | T5 | |
| GR3022121T3 | Greece | T3 | |
| DE68904999T3 | Germany | T3 |
67 legal events, as 4 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Nl: lapsed or anulled due to non-payment of the annual feeLapsedNLV4 | NLV4 | EP | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Be: lapsedLapsedBERE | BERE | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Validation in greece3022121FG4A | FG4A | GR | |
| Nl: decision of oppositionOppositionNLR2 | NLR2 | EP | |
| Nl: receipt of modified translations in the netherlands language after an opposition procedureOppositionNLR3 | NLR3 | EP | |
| Gb: translation of amended ep patent filed (gb section 77(6)(b)/1977)GBTA | GBTA | EP | |
| Patent modifiedDC2A | DC2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Scope or validity of the patent modifiedMAINTIEN DU BREVET DONT L'ETENDUE A ETE MODIFIEEAEN | AEN | CH | |
| Patent maintained in amended form27A | 27A | EP | |
| Designated contracting statesAK | AK | EP | |
| Patent maintained in amended formORIGINAL CODE: 0009272PUAH | PUAH | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: PATENT MAINTAINED AS AMENDEDSTAA | STAA | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Interlocutory decision in oppositionOppositionORIGINAL CODE: EPIDOS IDOPPLAW | PLAW | EP | |
| Interlocutory decision in oppositionOppositionORIGINAL CODE: EPIDOS IDOPPLAW | PLAW | EP | |
| Se: european patent in force in swedenEAL | EAL | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Lu: last paid annual feeEPTA | EPTA | EP | |
| Nl: opposition has been filed with the epoOppositionNLR1 | NLR1 | EP | |
| Nl: opposition has been filed with the epoOppositionNLR1 | NLR1 | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| Opposition filedOppositionORIGINAL CODE: 0009260PLBI | PLBI | EP | |
| Opposition filedOppositionORIGINAL CODE: 0009260PLBI | PLBI | EP | |
| Validation in greece3007265FG4A | FG4A | GR | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Gb: translation of ep patent filed (gb section 77(6)(a)/1977)GBT | GBT | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| Corresponds to:REF | REF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0349429
- Publication, DOCDB
- 0349429
- Publication, EPODOC
- EP0349429
- Application
- 89401857
- Application, DOCDB
- 89401857
- Application, EPODOC
- EP19890401857
Titles3
- German
- Verfahren zur Herstellung dispergierbarer kolloidaler Systeme aus amphiphilen Lipiden in Form von Liposomen in Submikrongrösse
- English
- Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of submicronic liposomes
- French
- Procédé de préparation de systèmes colloidaux dispersibles de lipides amphiphiles sous forme de liposomes submicroniques
Classification
- CPC, 1
- A61K9/1277
- IPC, 5
- A61K8 11
- A61K8 14
- A61K8 34
- A61K9 127
- B01J13 02
Designated states13
- Contracting states, 13
- Austria
- Belgium
- Switzerland
- Germany
- Spain
- France
- United Kingdom
- Greece
- Italy
- Liechtenstein
- Luxembourg
- Netherlands (Kingdom of the)
- Sweden